To investigate the effects of human endostatin on proliferation of human umbilical venous endothelial cells, the apoptosis of the endothelial cells treated with recombinant human endostatin was examined by fluorescence method and the cell proliferation activity analyzed by MTT assay. The results showed that human endostatin inhibited the proliferation of the endothelial cells with ED(50) of 550 ng/ml, and the inhibitory effect was enhanced with the increase of endostatin concentration, suggesting a dose-dependent inhibitory effect of human endostatin on endothelial cell proliferation. The mechanism of antiangiogenesis induced by human endostatin is related to the inhibition of cell proliferation and induction of apoptosis of the endothelial cells.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Association between endostatin and mortality in patients with acute dyspnoea, with or without congestive heart failure: a single-centre, prospective, observational study.
BMJ Open
January 2025
Emergency Department, Skåne University Hospital, Malmo, Skåne, Sweden
Objective: The aim of this study was to assess associations between endostatin levels and short-term mortality in unsorted acute hospitalised dyspnoea patients with or without congestive heart failure (CHF), adjusted for common cardiovascular risk factors.
Design, Setting And Participants: In this prospective observational study, 723 hospitalised patients who visited the emergency department at Skåne University Hospital, Sweden, between 2013 and 2018 were included. Of these, 276 had a history of CHF.
Endostatin as a biomarker of systemic sclerosis: insights from a systematic review and meta-analysis.
Front Immunol
January 2025
Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
Introduction: The critical role played by vascular dysfunction and ineffective angiogenesis in the pathophysiology of systemic sclerosis (SSc) suggests that circulating biomarkers reflecting these alterations may be useful in the clinical evaluation of this patient group. We sought to address this issue by conducting a systematic review and meta-analysis of studies investigating a such candidate biomarker, endostatin, an endogenous glycoprotein exerting anti-angiogenic effects, in SSc patients and healthy controls.
Methods: A literature search was conducted in the electronic databases Web of Science, PubMed, and Scopus from inception to 27 May 2024.
Endostatin in disease modulation: From cancer to beyond.
Vascul Pharmacol
December 2024
Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Mohali 160062, Punjab, India. Electronic address:
Angiogenesis plays a pivotal role in various pathological conditions, making it a key target in therapeutic development. Anti-angiogenic therapies are gaining traction for their potential in treating a range of angiogenesis-dependent diseases. Among these, endogenous angiogenesis inhibitors, particularly endostatin, have garnered significant attention for their therapeutic potential.
View Article and Find Full Text PDFBeyond Hormones: A Systematic Review of the Risk of Cardiovascular Diseases in Polycystic Ovary Syndrome.
Cureus
November 2024
Internal Medicine, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, IND.
Polycystic ovary syndrome (PCOS) is a common endocrinopathy among women in the reproductive age group. PCOS is defined by the Rotterdam criteria, which include hyperandrogenism, oligo-anovulation, and polycystic ovaries on ultrasound. The common symptoms are irregular or absent periods, acne, hirsutism, and alopecia androgenica.
View Article and Find Full Text PDFModeling Lymphoma Angiogenesis, Lymphangiogenesis, and Vessel Co-Option, and the Effects of Inhibition of Lymphoma-Vessel Interactions with an αCD20-EndoP125A Antibody Fusion Protein.
Cells
November 2024
Division of Hematology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Lymphoma growth, progression, and dissemination require tumor cell interaction with supporting vessels and are facilitated through tumor-promoted angiogenesis, lymphangiogenesis, and/or lymphoma vessel co-option. Vessel co-option has been shown to be responsible for tumor initiation, metastasis, and resistance to anti-angiogenic treatment but is largely uncharacterized in the setting of lymphoma. We developed an in vitro model to study lymphoma-vessel interactions and found that mantle cell lymphoma (MCL) cells co-cultured on Matrigel with human umbilical vein (HUVEC) or human lymphatic (HLEC) endothelial cells migrate to and anneal with newly formed capillary-like (CLS) or lymphatic-like (LLS) structures, consistent with lymphoma-vessel co-option.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!